Chi Chun Wu

US Patent:

6891803, May 10, 2005

Filed:

Dec 18, 1998

Appl. No.:

09/215421

Inventors:

Paul Chang - Fremont CA, US
Tom Dang - San Jose CA, US
Chi Lin Wu - San Jose CA, US

Assignee:

Sunrise Telecom, Inc. - San Jose CA

International Classification:

H04L012/66

US Classification:

370252, 370248, 370251, 370247, 379 21, 379 1001, 348192, 714715

Abstract:

A test set includes at least one signal input port, a test circuitry, a processor, a user-input device, and a display. The test circuitry couples to and receives signals from the at least one signal input port. The test circuitry then generates test data corresponding to the received signals. The processor couples to and receives test data from the test circuitry and generates test results. The processor also couples to and receives commands from the user-input device. The processor further operatively couples to the graphical display that receives and displays the test results from the processor. In one embodiment, the test set is capable of performing line qualification and connectivity testing. A modem module can be used to facilitate connectivity testing. The modem module can be a plug-in module with a common interface to the test set.

US Patent:

6917595, Jul 12, 2005

Filed:

Oct 8, 2002

Appl. No.:

10/267191

Inventors:

Paul Chang - Fremont CA, US
Tom Dang - San Jose CA, US
Chi Lin Wu - San Jose CA, US

Assignee:

Sunrise Telecom, Inc. - San Jose CA

International Classification:

G01R031/08
G06F011/00
G08C015/00
H04J001/16
H04L001/00

US Classification:

370248, 370252, 370251, 370247, 379 2201, 379 2202, 379 2203, 714715

Abstract:

A test set includes at least one signal input port, a test circuitry, a processor, a user-input device, and a display. The test circuitry couples to and receives signals from the at least one signal input port. The test circuitry then generates test data corresponding to the received signals. The processor couples to and receives test data from the test circuitry and generates test results. The processor also couples to and receives commands from the user-input device. The processor further operatively couples to the graphical display that receives and displays the test results from the processor. In one embodiment, the test set is capable of performing line qualification and connectivity testing. A modem module can be used to facilitate connectivity testing. The modem module can be a plug-in module with a common interface to the test set.

US Patent:

7656807, Feb 2, 2010

Filed:

Apr 5, 2005

Appl. No.:

11/099983

Inventors:

Paul Chang - Fremont CA, US
Tom Dang - San Jose CA, US
Chi Lin Wu - San Jose CA, US

Assignee:

Sunrise Telecom Incorporated - San Jose CA

International Classification:

G01R 31/00
H04L 12/26

US Classification:

370241, 370250, 379 21, 379 103, 379 906

Abstract:

A test set includes at least one signal input port, a test circuitry, a processor, a user-input device, and a display. The test circuitry couples to and receives signals from the at least one signal input port. The test circuitry then generates test data corresponding to the received signals. The processor couples to and receives test data from the test circuitry and generates test results. The processor also couples to and receives commands from the user-input device. The processor further operatively couples to the graphical display that receives and displays the test results from the processor. In one embodiment, the test set is capable of performing line qualification and connectivity testing. A modem module can be used to facilitate connectivity testing. The modem module can be a plug-in module with a common interface to the test set.

US Patent:

60049278, Dec 21, 1999

Filed:

Jun 5, 1995

Appl. No.:

8/462757

Inventors:

Leslie Benet - Belvedere CA
Chi Yuan Wu - San Francisco CA

Assignee:

Regents of the University of California - Oakland CA

International Classification:

A61K 31015
A61K 3112
A61K 3113
A61K 3812

US Classification:

514 9

Abstract:

A method for increasing bioavailability of an orally administered hydrophobic pharmaceutical compound, which comprises orally administering the pharmaceutical compound to a mammal in need of treatment with the compound concurrently with a bioenhancer comprising an inhibitor of a cytochrome P450 3A enzyme or an inhibitor of P-glycoprotein-mediated membrane transport, the bioenhancer being present in sufficient amount to provide bioavailability of the compound in the presence of the bioenhancer greater than the bioavailability of the compound in the absence of the bioenhancer.

US Patent:

60280549, Feb 22, 2000

Filed:

May 6, 1998

Appl. No.:

9/073704

Inventors:

Leslie Z. Benet - Belvedere CA
Chi Yuan Wu - San Francisco CA

Assignee:

The Regents of the University of California - Oakland CA

International Classification:

A61K 31015
A61K 3112
A61K 3113
A61K 3812

US Classification:

514 9

Abstract:

A method for increasing bioavailability of an orally administered hydrophobic pharmaceutical compound, which comprises orally administering the pharmaceutical compound to a mammal in need of treatment with the compound concurrently with a bioenhancer comprising an inhibitor of a cytochrome P450 3A enzyme or an inhibitor of P-glycoprotein-mediated membrane transport, the bioenhancer being present in sufficient amount to provide bioavailability of the compound in the presence of the bioenhancer greater than the bioavailability of the compound in the absence of the bioenhancer.

US Patent:

55675921, Oct 22, 1996

Filed:

Feb 2, 1994

Appl. No.:

8/190288

Inventors:

Leslie Benet - Belvedere CA
Chi Y. Wu - San Francisco CA

Assignee:

Regents of the University of California - Oakland CA

International Classification:

G01N 33567
G01N 3353
C12Q 100

US Classification:

435 721

Abstract:

A screening method for the identification of bioenhancers that increase the bioavailability of an orally administered pharmaceutical compound through the inhibition of P-glycoprotein transport activity in the gut of a mammal is disclosed. These compounds increase the systemic availability of a pharmaceutical compound when administered prior to, or concurrently with, that compound.